When In-Person Ketamine Is Required

The telehealth at-home model is appropriate for a carefully selected subset of patients. Others require the closer monitoring, higher bioavailability, and immediate clinical response capability that only in-person IV ketamine in a supervised setting can provide. Understanding when in-person treatment is the appropriate choice—not just an option—is important for safe prescribing and for patients evaluating their options.

The Fundamental Difference: Monitoring Capability

The primary reason in-person ketamine is required for certain patients is not the drug itself—it is the monitoring and response capability that accompanies in-person delivery. At an IV ketamine clinic:

• A clinician is physically present throughout the infusion
• IV access allows immediate medication administration if needed
• Emergency equipment is on hand
• Dose titration can be performed in real time based on the patient's response
• The clinical team can directly observe subtle signs of adverse effects

None of these capabilities exist in the at-home model (see our telehealth vs. in-person comparison for a detailed breakdown). When patients have characteristics that make these capabilities clinically necessary, in-person treatment is not merely preferable—it is required.

Medical Conditions Requiring In-Person Treatment

Significant Cardiovascular Disease

Ketamine reliably elevates blood pressure and heart rate. For most healthy adults, this is a manageable, self-limiting response. For patients with:

• Uncontrolled or poorly controlled hypertension
• History of significant cardiac arrhythmia
• Recent myocardial infarction or stroke
• Significant coronary artery disease
• Congestive heart failure

...the cardiovascular response to ketamine must be monitored and potentially managed in real time. Remote monitoring of a blood pressure cuff does not provide the response capability needed to manage a cardiovascular adverse event. For more on what at-home monitoring involves, see our monitoring requirements guide.

Significant Hepatic Disease

Ketamine is metabolized by the liver. Patients with significant hepatic impairment may have unpredictable ketamine metabolism, leading to prolonged or unexpectedly intense effects that require clinical monitoring and potential intervention.

Respiratory Conditions

While ketamine is notably safer than other anesthetics in terms of respiratory depression, patients with significant respiratory compromise (severe COPD, sleep apnea requiring BiPAP, or other serious respiratory conditions) may warrant closer monitoring than remote care provides.

History of Emergence Reactions

Some patients have a history of severe "emergence reactions"—agitation, confusion, or delirium as ketamine effects wear off—from prior ketamine or other anesthetic exposure. This history suggests a need for in-room monitoring and intervention capability.

Psychiatric Conditions Requiring In-Person Treatment

Active Suicidal Ideation with Plan or Intent

Telehealth ketamine is appropriate for some patients with passive suicidal ideation (thoughts of death without active plan or intent). Active suicidal ideation with a specific plan or recent attempt is not compatible with at-home treatment—the monitoring available is insufficient for this level of psychiatric risk.

Patients with active suicidal ideation who are candidates for ketamine due to its rapid anti-suicidal properties should receive treatment in an in-person setting where direct supervision is available.

Recent Psychiatric Hospitalization

Patients discharged within the past 3-6 months from a psychiatric hospitalization have recently demonstrated a level of psychiatric instability that warrants more intensive care than at-home telehealth can provide. The transition from inpatient or intensive outpatient to at-home telehealth should be gradual and accompanied by established outpatient care.

Active Psychosis

Active psychotic symptoms—hallucinations, delusions, disorganized thinking—are generally a contraindication to ketamine, which can exacerbate psychotic symptoms at higher doses. If there is any psychosis risk, in-person evaluation with psychiatric expertise is required before considering ketamine.

Severe Dissociative Symptoms

Patients with dissociative disorders (DID, severe DPDR) may have unpredictable responses to ketamine's dissociative effects. Specialized in-person evaluation and potentially in-person treatment with a dissociation-experienced clinician is warranted.

Active Bipolar I Disorder with Inadequate Mood Stabilization

As discussed in the bipolar disorder guide, patients with Bipolar I disorder who are not adequately mood-stabilized are better served by in-person monitoring, where a hypomanic or manic switch can be promptly identified and treated.

When At-Home Fails: Transitioning to In-Person

Sometimes at-home telehealth ketamine is the appropriate starting point, but the patient's response indicates a need to escalate to in-person:

Inadequate Response to Sublingual Ketamine

If a patient completes a full initial course of sublingual ketamine at adequate doses without meaningful response, escalation to IV ketamine (with its higher bioavailability and more potent effect) is the appropriate next step. This requires transition to an in-person clinic.

Adverse Cardiovascular Response

If a patient's blood pressure monitoring shows consistent hypertensive responses during sessions, the prescribing provider should evaluate whether continuing at-home treatment is appropriate or whether in-person monitoring is warranted.

Emerging Psychological Concerns

If a patient begins showing signs of destabilization—increased anxiety between sessions, emerging dissociative symptoms, behavioral changes suggesting dependency—a provider should consider whether at-home treatment should continue or whether in-person evaluation and potentially in-person treatment is needed.

Finding In-Person Providers

For patients who require in-person ketamine:

• ASKP3 (American Society of Ketamine Physicians, Psychotherapists, and Practitioners): Maintains a provider directory
• KetamineClinicDirectory.com: Lists in-person IV ketamine clinics
• Your referring psychiatrist: Can often provide referrals to in-person programs in your area

The availability of in-person IV ketamine has expanded significantly. Most major metropolitan areas have multiple clinics; even many smaller cities have at least one. For patients in rural areas, the travel investment for in-person treatment when medically necessary is worthwhile.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service